Skip to main content
. 2021 Mar;9(6):500. doi: 10.21037/atm-21-927

Figure 7.

Figure 7

The sensitivities of patients in the high- and low-risk group to immunotherapy and chemotherapy. (A) The differential sensitivities to chemotherapy in the high- and low-risk groups. (B) The differential responses to anti-CTLA4 and anti-PD-1 immunotherapy in patients in the high- and low-risk groups. CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1.